A similar trend was evident in KRASG12C-mutant (NRAS-KO) Lewis lung carcinoma cell lines40 when treated with a KRAS-G12C inhibitor AMG510 or trametinib (Fig. S4i). This evidence concerns the gene NRAS and Carcinoma, Lewis Lung.